© 2023 MJH Life Sciences and Cancer Network. All rights reserved.
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
November 02, 2022
Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.
Drs Cowan and Anderson review whether older agents such as isa-based regimens still have a place in R/R MM treatment after the introduction of bispecific agents and CAR-T therapy.
October 26, 2022
Dr Silbermann continues her discussion of BCMA-targeting agents with a look at data on the use of bispecific agents for R/R MM treatment after a patient has already received a BCMA therapy.
Key opinion leaders compare the overall benefits of CAR-T therapy and share some advice for managing the toxicities of CAR-T therapy as a patient transitions back to their local doctor.
October 19, 2022
Drs Sidana and Silbermann describe the currently available treatment options for early- and late-relapse MM, and how to select an appropriate regimen.
An explanation of the mechanism of action of bispecific antibodies and their use in relapsed/refractory multiple myeloma treatment.
October 12, 2022
Dr Caitlin Costello discusses how she adapts treatment to patients with transplant-ineligible NDMM based on fitness level, and why some patients receive doublet therapy.
Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.
October 06, 2022
Dr Larry Anderson summarizes the study design and updated data of the MAIA trial, and Dr Rebecca Silbermann compares it against the SWOG 0777 trial.
Andrew Cowan, MD, presents the results of the ENDURANCE study comparing two triplet regimens in transplant-ineligible MM.